Patrick J. Christmas II
Net Worth

Last updated:

What is Patrick J. Christmas II net worth?

The estimated net worth of Mr. Patrick J. Christmas II is at least $5,591,623 as of 12 Feb 2021. He owns shares worth $137,523 as insider, has earned $1,162,120 from insider trading and has received compensation worth at least $4,291,980 in null.

What is the salary of Patrick J. Christmas II?

Mr. Patrick J. Christmas II salary is $613,140 per year as Senior Vice President & Chief Legal Officer in null.

How old is Patrick J. Christmas II?

Mr. Patrick J. Christmas II is 54 years old, born in 1971.

What stocks does Patrick J. Christmas II currently own?

As insider, Mr. Patrick J. Christmas II owns shares in one company:

Company Title Shares Price per share Total value
(RGNX) Senior Vice President & Chief Legal Officer 16,372 $8.4 $137,523

What does do?

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX logo
RGNX
$8.4

Patrick J. Christmas II insider trading

Mr. Patrick J. Christmas II has made 22 insider trades between 2018-2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 15,000 units of RGNX stock on 9 May 2018. As of 12 Feb 2021 he still owns at least 16,372 units of RGNX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 4,701 N/A N/A
Option
Employee Stock Option (Right to Buy) 4,701 N/A N/A
Sale
Common Stock 4,701 N/A N/A
Option
Common Stock 1,300 N/A N/A
Option
Employee Stock Option (Right to Buy) 1,300 N/A N/A
Sale
Common Stock 1,300 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 $44.95 $449,500
Sale
Common Stock 1,378 N/A N/A
Option
Stock Option (Right to Buy) 1,378 N/A N/A
Option
Common Stock 1,378 N/A N/A
Option
Employee Stock Option (Right to Buy) 7,500 N/A N/A
Option
Stock Option (Right to Buy) 2,622 N/A N/A
Option
Common Stock 10,122 N/A N/A
Sale
Common Stock 10,122 N/A N/A
Option
Employee Stock Option (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 $47.33 $473,270
Option
Common Stock 10,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,486 N/A N/A
Option
Employee Stock Option (Right to Buy) 5,000 N/A N/A
Option
Stock Option (Right to Buy) 4,900 N/A N/A
Sale
Common Stock 4,900 N/A N/A
Option
Common Stock 4,900 N/A N/A
Sale
Common Stock 100 N/A N/A
Option
Common Stock 100 N/A N/A
Option
Stock Option (Right to Buy) 100 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 3,541 N/A N/A
Option
Stock Option (Right to Buy) 1,459 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 $47.87 $239,350
Option
Employee Stock Option (Right to Buy) 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 1,528 N/A N/A
Option
Common Stock 1,528 N/A N/A
Option
Employee Stock Option (Right to Buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 15,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 15,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 10,000 N/A N/A

key executives

executives and other stock owners filed with the SEC: